Dutasteride

In the 1990s GSK developed Dutasteride as a type dual 5 alpha reductase inhibitor that gained FDA approval in 2001. It functions by blocking both the type 1 and type 2 isoforms, of the enzyme to halt testosterone from being transformed into dihydrotestosterone ( DHT).This attribute is especially beneficial in addressing conditions like prostate hyperplasia ( BPH ) and male pattern baldness (androgenic alopecia). Dutasterides scope extends beyond finasteride as it addresses DHT production in tissues such, as the scalp,liver and prostate​​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.